Together, VCAM-1 in HSCs does not contribute to liver steatosis, inflammation or fibrosis development in the course of NAFLD/NASH, as assessed in two different experimental models. This evidence concerns the gene VCAM1 and metabolic dysfunction-associated steatotic liver disease.